Allotment of shares for the Sudeep Pharma IPO will be finalised today after the public issue witnessed a sharp jump in demand on the last day of bidding.
The three-day subscription window, which closed on November 25, saw the IPO race towards nearly 100 times subscription, reflecting strong interest across investor categories.
The retail portion was booked 15.65 times, while the QIB category saw extremely strong interest at 213.08 times. The NII segment also posted heavy demand with 116.72 times subscription.
Applicants can check their allotment status through the BSE website or the registrar, MUFG Intime India.
On the BSE website:
Visit the
Select ‘Equity’ and choose Sudeep Pharma Limited from the dropdown.
Enter your application number and PAN.
Fill in the captcha and click on Search to view your allotment result.
On the MUFG Intime India website:
Go to the
Select Sudeep Pharma Limited from the list of active issues.
Choose any one option — Application Number, Demat Account Number, or PAN.
Enter the details, complete the captcha, and click Submit to check your status.
After allotment, refunds for applicants who did not receive shares will be initiated, while successful bidders will get shares credited to their demat accounts.
The grey market premium (GMP) suggests a healthy debut for Sudeep Pharma. The latest GMP stands at Rs 87. Based on the upper price band of Rs 593, the stock is expected to list around Rs 680, indicating a potential gain of 14.67%.
Investor sentiment appears positive, driven by strong subscription numbers and a robust GMP, though actual listing gains will depend on broader market conditions on debut day.
The IPO is a book-built issue of Rs 895 crore. It includes a fresh issue of 0.16 crore shares worth Rs 95 crore and an offer for sale (OFS) of 1.35 crore shares worth Rs 800 crore.
The issue opened on November 21 and closed on November 25. Sudeep Pharma shares will list on both BSE and NSE, with a tentative listing date of November 28.
The price band for the IPO has been set between Rs 563 and Rs 593 per share.
(Disclaimer: The views, opinions, recommendations, and suggestions expressed by experts/brokerages in this article are their own and do not reflect the views of the India Today Group. It is advisable to consult a qualified broker or financial advisor before making any actual investment or trading choices.)